logo
Share SHARE
FONT-SIZE Plus   Neg

ACADIA Pharmaceuticals Inc. (ACAD) Is Up On FDA Breakthrough Designation

ACADIA Pharmaceuticals Inc. (ACAD) announced after the bell Wednesday that the FDA has granted Breakthrough Therapy Designation to pimavanserin for dementia-related psychosis.

The company also announced that it has launched a Phase 3 study to evaluate pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis.

ACADIA Pharmaceuticals climbed during the middle portion of Wednesday's session and closed up by 0.28 at $39.14. The stock is now up 2.31 on 562K shares after the bell.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT